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Interventional Management of a Renal
Cell Carcinoma by Radiofrequency
Ablation with Tagging and Cooling
Over the last few years, percutaneous radiofrequency (RF) ablation has been
successfully established as a viable treatment modality for small peripheral renal
cell carcinoma (RCC). This technique is limited by central tumor location and
tumor size. We report the interventional management of a 5.3 cm mixed RCC
with central and exophytic parts by combining the RF ablation with embolization,
tagging, and retrograde, as well as anterograde cooling. The potential pitfalls of
complex hybrid interventions for treating RCC are discussed.
enal cell carcinoma (RCC) is the most frequent malignancy of the
kidneys. The increasing availability of US, CT and MR imaging in recent
years has led to a higher rate of incidentally diagnosed RCCs. For 2008,
more than 54,000 new cases of renal and uropelvic carcinomas are estimated to be
detected in the United States alone. The standard therapy for non-metastatic and local
RCC is a nephrectomy or nephron-sparing surgery; whereas target drug therapy or
immunotherapy is used in metastatic renal cell carcinoma. Minimally invasive options
include laparoscopic nephron-sparing surgery, cryoablation, and radiofrequency (RF)
ablation. As RCCs typically stay asymptomatic for a long while, the late onset in life
implies an increased rate and gravity of comorbidities amongst RCC patients,
ultimately leading to a considerably higher demand for the nonsurgical treatment of
RCC. 
Radiofrequency ablation has become an important therapeutic alternative for differ-
ent kinds of neoplasms; not only kidney cancer. Percutaneous RF ablation is associated
with a relatively low number of undesired side effects and complications due to its
minimally invasive and locally acting nature. It is especially useful for patients that are
ineligible for or refusing surgery. Various studies reported on the successful application
of RF ablation in renal tumors (1-3). One of the most relevant problems is the possible
damage to the collecting system during the procedure, which can cause considerable
morbidity (2). Moreover, in central or mixed lesions with central and exophytic parts,
complete ablation is not consistently achieved with incomplete ablation in up to 39%
of patients (4). Therefore, RF ablation is commonly rejected in central renal lesions.
Retrograde cooling of the collecting system has been cited as having the ability to
overcome this limitation (5, 6). Anterograde chilling of the collecting system via a
percutaneous nephrostomy has only been reported in the treatment of transitional cell
carcinoma of the renal pelvis (7). Another issue in renal RF ablation is the fact that
most renal neoplasms are not visible on non-enhanced CT scans. Therefore the
application of a contrast agent is necessary. However, the administration of a
potentially nephrotoxic contrast agent may be contraindicated, in particular for
patients suffering from renal insufficiency.
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RWe present a case where the combination of multiple
interventional techniques led to the solution of a set of
treatment-complicating problems, and ultimately to the
successful ablation of a central RCC in a patient suffering
from renal insufficiency.
CASE REPORT
A 77-year-old woman presenting with a one month
history of progredient dyspnea underwent an unenhanced
computed tomography (CT) scan of the chest, which
incidentally revealed a largely hyperdense upper pole
lesion in the left kidney with a maximum diameter of 5.3
cm (Fig. 1A). Parts of the lesion attained the renal pelvis.
This finding was confirmed by ultrasound. An ultrasound-
guided fine needle aspiration biopsy revealed RCC of the
clear cell type (T1b N0 M0) (Fig. 1). She also suffered from
primary hypertension (BP [blood pressure] 140-150/100
mmHg), chronic obstructive pulmonary disease, dilated
cardiomyopathy and implantation of a cardiac pacemaker,
mitral insufficiency (NYHA [New York Heart Association]
III), insulin-dependent diabetes mellitus (fasting glucose
value: 100-110 mg/dl), chronic renal failure (creatinine
level: 1.5 mg/dl), and alcoholic liver cirrhosis. Due to the
markedly elevated perioperative risk (ASA [American
Society of Anesthesiology] IV) the patient refused surgery.
Subsequently, the patient was referred for interventional
treatment of the tumor. A percutaneous RF ablation was
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Fig. 1. Renal tumor before (arrows in A), during (* in B), and after (arrows in C) embolization of its central part with iodinated oil.
Embolization was focused on central part of mixed tumor in order to achieve sufficient tagging of this area. Multi-planar reformations from
intra-procedural CT images (D, E) illustrate positioning of radiofrequency probe and its relation to cooling catheters (* in E, F = RF probe;
arrowhead in E = internal catheter; arrows in E = external cooling catheter). Central part of tumor reaches collecting system, which is
marked by external cooling catheter. Follow-up CT scan eight months after intervention reveals no signs of local tumor recurrence (F).
Note residual iodinated oil at site of ablation (arrows).
DEFconsidered to be the most suitable therapeutic option. Due
to the size of the lesion, the patient was scheduled for pre-
interventional embolization of the central part of her
tumor in order to achieve central necrosis and a more
homogeneous heat distribution in the devascularized parts
of the tumor. Iodinated oil (Lipiodol Ultra-Fluid
�, Guerbet,
Roissy, France) was considered for lesion tagging since it
provides post-embolization contrast and allows for CT-
guided placement of the RF-probe without use of
additional contrast agent. 
Embolization was performed via the right femoral
approach using a 4 Fr introducer sheath. After selective
catheterization of the left renal artery using a 4 Fr
sidewinder catheter (Merit Medical, South Jordan, UT), a 3
Fr microcatheter (Progreat, Terumo, Tokyo, Japan) was
placed in the tumor feeding vessels in the upper pole of the
kidney. The tumor was subsequently embolized using 10
ml of iodinated oil (Lipiodol, Guerbet, Roissy, France) (Fig.
1B, C). Considering the patient’s delicate renal condition,
the use of iodinated contrast agent was limited to 10 ml
(Visipaque 320, GE Healthcare, Princeton, NJ). 
Prior to the RF ablation, a single-J catheter was placed in
the left ureter with its tip in the collecting system, to
accomplish external renal pelvis cooling. Preliminary
testing of the single-J catheter only allowed for a drop-by-
drop injection, which was insufficient for cooling and
protection from thermal damage. Since the patient rejected
conscious sedation, the procedure was performed under
general anesthesia. Accordingly, the patient was positioned
in the right lateral decubitus position; and, following an
unenhanced CT (SOMATOM Sensation 16, Siemens,
Forchheim, Germany; 16 × 0.75 mm, 120 kV, 165
mAseff), a CT-guided nephrostomy was performed using
the trocar technique with a 6.5 Fr drainage (Resolve, Merit
Medical, South Jordan, UT) to achieve sufficient cooling
via the anterograde approach. Continuous cooling of the
upper calices was performed with pre-chilled (8℃) 0.9%
saline infused at a flow rate of 500 ml/h.
For RF ablation, four grounding pads were placed on the
patient’s proximal thighs. The procedure was carried out
using a monopolar RF system (RF 3000, Boston Scientific
Corporation, Natick, MA) in combination with a 5 cm
umbrella-shaped LeVeen probe (Boston Scientific). Prior to
the RF probe placement, the distal 1 cm of the probe
insulation was removed to allow for post-interventional
coagulation of the puncture tract. The electrode was placed
under CT-guidance in the centre of the lesion (Fig. 1D, E).
After the final probe position was confirmed, energy was
applied according to the manufacturer’s recommendations
for soft tissue ablation. Ablation was performed using the
pullback technique at two positions, and achieving two
complete roll-offs at each position. The total time of
ablation was 74 minutes. Arterial and venous phase CT
scan (SOMATOM Sensation 16, Siemens, Forchheim,
Germany; 16×0.75 mm, 120 kV, 165 mAseff) with a
reduced amount of contrast agent (80 ml Iodixanol,
Visipaque, GE Healthcare) showed a completely devascu-
larized tumor, with no sign of any residual contrast
enhancement. Thereafter, the RF probe was gradually
retracted under continuous coagulation of the puncture
tract by applying 20 W. 
No early or delayed complications were noted; however,
due to her general condition, the patient was temporarily
admitted to the intermediate care unit for observation. She
recovered well and the single-J splint was removed a day
after and the nephrostomy five days after the ablation. The
patient was discharged the following day in good
condition. A CT performed at eight months after the
procedure, showed residual Lipiodol in the area of the
ablation without signs of local renal tumor recurrence (Fig.
1F).
DISCUSSION
The RF ablation of renal tumors has recently been
established as a viable treatment modality and is especially
well suited in the case of single kidney, hereditary RCC,
multiple renal lesions, and patients who are not eligible for
surgery or who refuse surgery. Although no randomized
trials have been performed, recent data in 100 tumors
showed encouraging results with regards to the efficacy
and safety of renal RF ablation (1, 4). However, there is no
long term outcome data. Small tumor size (< 3 cm) and a
peripheral tumor localization are considered to be predic-
tors for successful ablation (1, 2). For larger tumors,
additional embolization has been performed to achieve
more homogeneous heating, and thereby an improved
outcome (2, 10). For centrally located tumors, collecting
system cooling has been proposed as a method to protect
these structures from thermal damage. Cooling is typically
performed in a retrograde way, thereby avoiding another
percutaneous approach (5, 6); although, anterograde
cooling via nephrostomy is feasible. This, however, has,
thus far, only been described for transitional cell carcinoma
(7). The unique feature of this case is the combination of
different auxiliary techniques that improve the efficacy
and safety of the procedure in an otherwise inoperable
tumor. 
Some authors propose transarterial embolization as the
sole treatment for RCC in patients who are unfit for
surgery (8). While this technique is known to be effective
as a palliative measure in symptomatic patients, there is
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embolization as sole treatment of RCCs (9). Therefore, we
opted for a combined treatment of embolization of the
central part of the mixed tumor, followed by the RF
ablation as a definitive treatment. The embolization of the
tumor has to be considered as a neo-adjuvant approach, to
achieve complete ablation in tumors exceeding 3 cm (2,
10). The choice of Lipiodol for this procedure, although
not permanently occluding the tumor feeding vessels,
allowed for continuous visualization of the critical part of
the target without the need for additional contrast agent in
a patient with renal insufficiency. In a follow-up scans at
eight months after the intervention, there was an iodinated
oil residuum visible, indicating ceased perfusion of the
treated area. Anterograde cooling via nephrostomy was
applied when the initially planned retrograde cooling of
the collecting system proved to be insufficient. With the
single-J catheter still in place, this allowed for high flow of
the chilled saline. 
A major disadvantage for the use of multiple auxiliary
techniques lies in the fact that the complication rate and
the total procedure time increases with each additional
measure. Those negative aspects need to be balanced
against the benefit the patient can take from these
measures. The key advantage of such combined
procedures is the feasibility to treat lesions that are
otherwise considered unsuited for interventional therapy.
Moreover, the synergistic combination of iodinated oil
tagging-embolization and internal (retrograde), in addition
to an external (anterograde) collecting system, cooling may
render the RF-based therapy of complex renal lesions
possible, providing a therapeutic option for well selected
patients, where no other treatment is feasible.
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